Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| humanized origin | 5308 | 915810-67-2 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
|
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 30, 2018 | EMA | ABLYNX NV | |
| Feb. 6, 2019 | FDA | ABLYNX NV | |
| Sept. 26, 2022 | PMDA | SANOFI K.K. |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| ADAMTS13 activity decreased | 491.00 | 45.57 | 56 | 1440 | 142 | 90626809 |
| Product use in unapproved indication | 377.83 | 45.57 | 156 | 1340 | 336080 | 90290871 |
| ADAMTS13 activity abnormal | 230.45 | 45.57 | 23 | 1473 | 0 | 90626951 |
| Epistaxis | 116.55 | 45.57 | 46 | 1450 | 85079 | 90541872 |
| Platelet count decreased | 98.55 | 45.57 | 47 | 1449 | 136922 | 90490029 |
| Off label use | 61.05 | 45.57 | 82 | 1414 | 1102170 | 89524781 |
| Injection site bruising | 56.84 | 45.57 | 24 | 1472 | 52283 | 90574668 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| ADAMTS13 activity decreased | 176.43 | 42.20 | 21 | 476 | 131 | 42620707 |
| Product use in unapproved indication | 145.38 | 42.20 | 60 | 437 | 184396 | 42436442 |
| ADAMTS13 activity abnormal | 103.69 | 42.20 | 10 | 487 | 0 | 42620838 |
| Platelet count decreased | 48.46 | 42.20 | 26 | 471 | 138555 | 42482283 |
| Platelet count abnormal | 44.74 | 42.20 | 10 | 487 | 3639 | 42617199 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| ADAMTS13 activity decreased | 596.51 | 35.70 | 71 | 1936 | 258 | 110587034 |
| Product use in unapproved indication | 508.65 | 35.70 | 215 | 1792 | 447162 | 110140130 |
| ADAMTS13 activity abnormal | 297.73 | 35.70 | 30 | 1977 | 0 | 110587292 |
| Epistaxis | 137.19 | 35.70 | 60 | 1947 | 130312 | 110456980 |
| Platelet count decreased | 104.78 | 35.70 | 60 | 1947 | 230383 | 110356909 |
| Platelet count abnormal | 88.76 | 35.70 | 21 | 1986 | 6261 | 110581031 |
| Injection site bruising | 71.87 | 35.70 | 29 | 1978 | 51234 | 110536058 |
| Off label use | 69.72 | 35.70 | 108 | 1899 | 1500077 | 109087215 |
| Gingival bleeding | 45.13 | 35.70 | 16 | 1991 | 19823 | 110567469 |
| Contusion | 41.28 | 35.70 | 34 | 1973 | 233327 | 110353965 |
| Injection site pain | 38.05 | 35.70 | 29 | 1978 | 177893 | 110409399 |
| Platelet count increased | 37.23 | 35.70 | 15 | 1992 | 26319 | 110560973 |
None
| Source | Code | Description |
|---|---|---|
| ATC | B01AX07 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents |
| CHEBI has role | CHEBI:50249 | anticoagulant |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Thrombotic thrombocytopenic purpura | indication | 78129009 | DOID:10772 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| von Willebrand factor | Secreted | ANTIBODY BINDING | Kd | 8.51 | IUPHAR | DRUG LABEL |
| ID | Source |
|---|---|
| 2R27AB6766 | UNII |
| 4038197 | VANDF |
| 4038198 | VANDF |
| C3713057 | UMLSCUI |
| CHEBI:754365 | CHEBI |
| CHEMBL2109624 | ChEMBL_ID |
| DB06081 | DRUGBANK_ID |
| D11160 | KEGG_DRUG |
| 9511 | INN_ID |
| C585343 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9123 | IUPHAR_LIGAND_ID |
| 784411004 | SNOMEDCT_US |
| 789447000 | SNOMEDCT_US |
| 36265 | MMSL |
| 36266 | MMSL |
| d09171 | MMSL |
| 017896 | NDDF |
| 2110604 | RXNORM |
None